|
|
|
| Drug therapy and prognostic factors of postmenopausal women with breast cancer |
| FANG Jian1 WEN Shimin2 ZHAO Junjian1 TANG Zhili1 ZHANG Xinping2 CHEN Silin2 |
1. Department of Pharmacy, Nanchong Central Hospital, Sichuan Province, Nanchong 637000, China;
2.Department of Oncology, Nanchong Central Hospital, Sichuan Province, Nanchong 637000, China |
|
|
|
Abstract Objective To analyze the efficacy, safety and the related factors of S-1 and Capecitabine in treatment of advanced breast cancer in postmenopausal women's. Methods From January 2013 to June 2015, 61 cases of menopausal women with advanced breast cancer admitted to Department of Oncology in Nanchong Central Hospital were selected as subjects, and all subjects were randomly divided into S-1 treatment group (31 cases) and Capecitabine treatment group (30 cases) by random number table. The clinical efficacy and prognosis of the two groups were compared and prognostic factors of all patients were analyzed. Results There was no significant difference in rate of ORR (32.26% vs. 30%, χ2=0.036, P=0.849), DCR (67.74% vs. 63.33%, χ2=0.131, P=0.717) in S-1 group and Capecitabine group, and there was no significant difference in median PFS time between the two groups (5.7 months vs. 5.1 months, χ2=0.107, P=0.744). The incidence of hyperbilirubinemia of the S-1 group was higher than that of the Capecitabine group (χ2=10.227, P=0.001), and the incidence of hand foot syndrome of the Capecitabine group was higher than that of the S-1 group (χ2=10.377, P=0.001). Disease free survival and the number of metastases was independent factors of PFS. Conclusion The clinical efficacy of S-1 and Capecitabine in treatment of advanced breast cancer in postmenopausal women is equivalent, and all can obtain good curative effect, the adverse reaction is slightly different, but all can be tolerated.
|
|
|
|
|
|
[1] Siegel RL，Miller KD，Jemal A. Cancerstatistics，2017 [J]. CA Cancer J Clin，2017，64（1）：7-30.
[2] 刘保华，万舰，余婉燕，等.乳腺癌危险因素调查分析[J].河南医学研究，2017，26（21）：3844-3847.
[3] 王珊，石红宇，孔雯雯，等.中国高发乳腺癌危险因素的最新进展[J].临床护理杂志，2017，16（1）：72-75.
[4] 罗年安，屈亚琦，董瑞.乳腺癌的治疗进展[J].现代生物医学进展，2015，15（1）：160-162，166.
[5] 王昕怡，张珍，邵加庆.乳腺癌的内分泌治疗新进展[J].中国全科医学，2012，15（3C）：959-962.
[6] 陈占红，王晓稼.晚期乳腺癌药物研究与治疗进展[J].临床药物治疗杂志，2014，12（2）：1-6.
[7] 王铁军，耿慧，祝永刚，等.乳腺癌化疗现状及相关研究进展[J].现代生物医学进展，2013，13（22）：4398-4400.
[8] 汪颖，贾卫娟，饶南燕，等.含卡培他滨方案一线或后线治疗晚期乳腺癌的疗效比较[J].中华肿瘤防治杂志，2016， 23（15）：1006-1010，1015.
[9] Yuan P，Di LJ，Liu W，et al. PhaseⅡmulti-center clinical study on using s-1 to treat advanced breast cancer after resistance to anthracycline and taxane drugs in Chinese patients [J]. Int J Clin Med，2015，8（2）：3072-3079.
[10] Chen AP，Setser A，Anadkat MJ，et al. Grading dermatologic adverse events of cancer treatments： The common terminology criteria for adverse events version 4.0 [J]. Journal of the American Academy of Dermatology，2012， 67（5）：1025-1039.
[11] 陈万青，郑荣寿.中国女性乳腺癌发病死亡和生存状况[J].中国肿瘤临床，2015，42（13）：668-674.
[12] 陈军，曹亚丽，吴晓波，等.老年转移性乳腺癌患者中等剂量单药卡培他滨的应用效果及预后分析[J].中国老年学杂志，2017，37（13）：3259-3260.
[13] 刘君，肖扬，马益慧，等.奥沙利铂联合替吉奥治疗难治性晚期乳腺癌临床观察[J].国际肿瘤学杂志，2016，43（5）：330-334.
[14] 盛晶，万里新，屈中玉.洛铂与顺铂分别联合替吉奥治疗晚期转移性乳腺癌的疗效比较[J].中国药房，2017， 28（24）：3377-3379.
[15] 林勇，李荣洲，宋胜江，等.替吉奥胶囊治疗老年胃癌患者对血清sICAM-1、Survivin及肿瘤标志物水平的影响[J].中华全科医学，2017，15（06）：971-973.
[16] 符开伙，张剑权，蒋明.替吉奥联合奥沙利铂辅助射频消融术治疗直肠癌根治术后肝转移的临床观察[J].中国药房，2017，28（18）：2496-2499.
[17] 焦洋，宁洁，王芳，等.晚期乳腺癌替吉奥与卡培他滨治疗疗效及安全性对比研究[J].中华肿瘤防治杂志，2016， 23（7）：452-456.
[18] Hong JY，Park YH，Choi MK，et al. Characterization of durable responder for Capecitabine monotherapy in patients with anthracycline-and Taxane-Pretreated Metastatic Breast Cancer [J]. Clin Breast Cancer，2015，15（5）：e287-e292.
[19] 吴菲，何丹丹，赵根明，等.上海市女性乳腺癌危险因素分析与风险预测模型研究[J].中华肿瘤防治杂志，2017， 24（12）：795-801，807.
[20] 张松峰，田华，潘立新.老年乳腺癌患者复发类型及其危险因素[J].中国老年学杂志，2013，33（19）：4722-4724. |
|
|
|
